Form 4: Stoke Therapeutics Director Sells Shares Under 10b5-1 Plan

Stoke Therapeutics Director Edward M. Kaye MD sold a total of 61,885 shares of common stock in late August and early September 2025, pursuant to a pre-arranged 10b5-1 trading plan.

Summary

• Edward M. Kaye MD, a Director of Stoke Therapeutics, Inc. (STOK), reported sales of common stock.
• Transactions occurred on August 29, 2025, September 2, 2025, and September 3, 2025.
• On August 29, 2025, 1,029 shares were sold at a price of $20.00 per share.
• On September 2, 2025, 14,860 shares were sold at a weighted average price of $20.1386 per share, with prices ranging from $20.00 to $20.40.
• On September 3, 2025, 45,996 shares were sold at a weighted average price of $20.1291 per share, with prices ranging from $20.00 to $20.40.
• The total number of shares sold across these three transactions is 61,885.
• All transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by Dr. Kaye on December 30, 2024.
• Following these transactions, Dr. Kaye beneficially owns 91,585 shares of Stoke Therapeutics common stock directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can sometimes be viewed negatively, these transactions were executed under a pre-arranged 10b5-1 trading plan, which typically indicates personal financial planning rather than a change in the director's outlook on the company's prospects.

Positives

• The sales were conducted under a Rule 10b5-1 trading plan, which demonstrates adherence to corporate governance best practices by pre-scheduling trades to avoid accusations of insider trading based on material non-public information.

Negatives

• Insider selling, even when pre-planned, can sometimes be perceived by the market as a lack of confidence in the company's near-term prospects, although this is less pronounced for 10b5-1 plans.

Risks

• Potential for negative market sentiment if investors misinterpret the planned insider sales as a reactive decision rather than a pre-scheduled financial management activity.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future financial performance or strategic direction.

Industry Context

Insider transactions, particularly those executed under Rule 10b5-1 plans, are a common practice across all industries, including biotechnology, for executives and directors to manage their personal financial portfolios while adhering to securities laws.

Corporate Governance

Stakeholder Impact

• Shareholders: May observe the director's reduction in direct ownership, though the pre-planned nature of the sales under a 10b5-1 plan typically mitigates significant concern.

Key Dates

Recommendation

The filing reports pre-scheduled insider sales by a director under a 10b5-1 plan. While insider selling is a data point, these are planned transactions for personal financial management and do not necessarily reflect a change in the company's fundamental outlook or operational performance. Therefore, this filing alone does not warrant a change in investment recommendation.

Keywords

Stoke Therapeutics, STOK, Insider Trading, Form 4, Stock Sale, Director, 10b5-1 Plan, Equity Transaction, Biotechnology